Acorah Software Products - Accounts Production 19.3.600 false true 30 November 2024 1 December 2023 false 1 December 2024 30 November 2025 30 November 2025 11473075 Mr Mitul Patel Mr Sanjay Patel iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 11473075 2024-11-30 11473075 2025-11-30 11473075 2024-12-01 2025-11-30 11473075 frs-core:CurrentFinancialInstruments 2025-11-30 11473075 frs-core:FurnitureFittings 2025-11-30 11473075 frs-core:FurnitureFittings 2024-12-01 2025-11-30 11473075 frs-core:FurnitureFittings 2024-11-30 11473075 frs-core:NetGoodwill 2025-11-30 11473075 frs-core:NetGoodwill 2024-12-01 2025-11-30 11473075 frs-core:NetGoodwill 2024-11-30 11473075 frs-core:LandBuildings frs-core:LeasedAssetsHeldAsLessee 2025-11-30 11473075 frs-core:LandBuildings frs-core:LeasedAssetsHeldAsLessee 2024-12-01 2025-11-30 11473075 frs-core:LandBuildings frs-core:LeasedAssetsHeldAsLessee 2024-11-30 11473075 frs-core:LandBuildings frs-core:OwnedOrFreeholdAssets 2025-11-30 11473075 frs-core:LandBuildings frs-core:OwnedOrFreeholdAssets 2024-12-01 2025-11-30 11473075 frs-core:LandBuildings frs-core:OwnedOrFreeholdAssets 2024-11-30 11473075 frs-core:MotorVehicles 2025-11-30 11473075 frs-core:MotorVehicles 2024-12-01 2025-11-30 11473075 frs-core:MotorVehicles 2024-11-30 11473075 frs-core:ShareCapital 2025-11-30 11473075 frs-core:RetainedEarningsAccumulatedLosses 2025-11-30 11473075 frs-bus:PrivateLimitedCompanyLtd 2024-12-01 2025-11-30 11473075 frs-bus:FilletedAccounts 2024-12-01 2025-11-30 11473075 frs-bus:SmallEntities 2024-12-01 2025-11-30 11473075 frs-bus:AuditExempt-NoAccountantsReport 2024-12-01 2025-11-30 11473075 frs-bus:SmallCompaniesRegimeForAccounts 2024-12-01 2025-11-30 11473075 frs-bus:Director1 2024-12-01 2025-11-30 11473075 frs-bus:Director2 2024-12-01 2025-11-30 11473075 frs-countries:EnglandWales 2024-12-01 2025-11-30 11473075 2023-11-30 11473075 2024-11-30 11473075 2023-12-01 2024-11-30 11473075 frs-core:CurrentFinancialInstruments 2024-11-30 11473075 frs-core:ShareCapital 2024-11-30 11473075 frs-core:RetainedEarningsAccumulatedLosses 2024-11-30
Registered number: 11473075
Suffolk Pharma Ltd
Financial Statements
For The Year Ended 30 November 2025
Suffolk Pharma Ltd
Contents
Contents

| Page
--- | ---
Balance Sheet | 1—2
Notes to the Financial Statements | 3—6

Page 1
Suffolk Pharma Ltd
Balance Sheet
As At 30 November 2025
Balance Sheet
Registered number: 11473075

| 2025 | 2024
--- | --- | ---
| Notes | £ | £ | £ | £
FIXED ASSETS
Intangible Assets | 4 |  | 748,852 |  | 1,075,490
Tangible Assets | 5 |  | 615,410 |  | 646,916
|  |  | 1,364,262 |  | 1,722,406
CURRENT ASSETS
Stocks |  | 124,274 |  | 194,469 |
Debtors | 6 | 3,903,615 |  | 3,335,610 |
Cash at bank and in hand |  | 851,372 |  | 320,611 |
|  | 4,879,261 |  | 3,850,690 |
Creditors: Amounts Falling Due Within One Year | 7 | (544,678 ) |  | (856,315 ) |
NET CURRENT ASSETS (LIABILITIES) |  |  | 4,334,583 |  | 2,994,375
TOTAL ASSETS LESS CURRENT LIABILITIES |  |  | 5,698,845 |  | 4,716,781
NET ASSETS |  |  | 5,698,845 |  | 4,716,781
CAPITAL AND RESERVES
Called up share capital |  |  | 1,000 |  | 1,000
Profit and Loss Account |  |  | 5,697,845 |  | 4,715,781
SHAREHOLDERS' FUNDS |  |  | 5,698,845 |  | 4,716,781

Page 1
Page 2
Suffolk Pharma Ltd
Balance Sheet (continued)
As At 30 November 2025
For the year ending 30 November 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
The financial statements were approved by the board of directors on 4 August 2026 and were signed on its behalf by:

Mr Sanjay Patel Director
4 August 2026

The notes on pages 3 to 6 form part of these financial statements.
Page 2
Page 3
Suffolk Pharma Ltd
Notes to the Financial Statements
For The Year Ended 30 November 2025
Notes to the Financial Statements
1. General Information
Suffolk Pharma Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 11473075 . The registered office is 205, Plumstead Road, Norwich, Norfolk, NR1 4AB.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.
Sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods has transferred to the buyer. This is usually at the point that the customer has signed for the delivery of the goods.
Rendering of services
Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
2.3. Intangible Fixed Assets and Amortisation - Goodwill
Goodwill is the difference between amounts paid on the acquisition of a business and the fair value of the separable net assets. It is amortised to profit and loss account over its estimated economic life of 20 years.
2.4. Tangible Fixed Assets and Depreciation
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Freehold | No depreciation
Leasehold | No depreciation
Motor Vehicles | 25% reducing balance
Fixtures, fittings and equipment | 15% reducing balance

2.5. Leasing and Hire Purchase Contracts
Assets obtained under finance leases are capitalised as tangible fixed assets. Assets acquired under finance leases are depreciated over the shorter of the lease term and their useful lives. Assets acquired under hire purchase contracts are depreciated over their useful lives. Finance leases are those where substantially all of the benefits and risks of ownership are assumed by the company. Obligations under such agreements are included in the creditors net of the finance charge allocated to future periods. The finance element of the rental payment is charged to the profit and loss account so as to produce a constant periodic rate of charge on the net obligation outstanding in each period.
Rentals applicable to operating leases where substantially all of the benefits and risks of ownership remain with the lessor are charged to the profit and loss account as incurred.
2.6. Stocks and Work in Progress
Stocks and work in progress are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads. Work-in-progress is reflected in the accounts on a contract by contract basis by recording turnover and related costs as contract activity progresses.
Page 3
Page 4
Suffolk Pharma Ltd
Notes to the Financial Statements (continued)
For The Year Ended 30 November 2025
2.7. Taxation
Income tax expense represents the sum of the tax currently payable and deferred tax.
The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.
Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.
Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and assets reflect the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.
Current and deferred tax are recognised in profit or loss for the year, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case current and deferred tax are recognised in other comprehensive income or directly in equity respectively.
2.8. Pensions
The company operates a defined pension contribution scheme. Contributions are charged to the profit and loss account as they become payable in accordance with the rules of the scheme.
2.9. Debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
2.10. Creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
2.11. Provisions
Provisions (ie liabilities of uncertain timing or amount) are recognised when there is an obligation at the reporting date as a result of a past event, it is probable that economic benefit will be transferred to settle the obligation and the amount of the obligation can be estimated reliably.
3. Average Number of Employees
Average number of employees, including directors, during the year was: 30 (2024: 38)
30 38
Page 4
Page 5
Suffolk Pharma Ltd
Notes to the Financial Statements (continued)
For The Year Ended 30 November 2025
4. Intangible Assets

| Goodwill
--- | ---
| £
Cost
As at 1 December 2024 | 1,363,115
Disposals | (386,560 )
As at 30 November 2025 | 976,555
Amortisation
As at 1 December 2024 | 287,625
Provided during the period | 63,324
Disposals | (123,246 )
As at 30 November 2025 | 227,703
Net Book Value
As at 30 November 2025 | 748,852
As at 1 December 2024 | 1,075,490

5. Tangible Assets

| Land & Property
--- | ---
| Freehold | Leasehold | Motor Vehicles | Fixtures, fittings and equipment | Total
| £ | £ | £ | £ | £
Cost
As at 1 December 2024 | 510,691 | 16,365 | 210,070 | 61,932 | 799,058
Additions | - | - | - | 2,531 | 2,531
Disposals | - | - | - | (18,581 ) | (18,581 )
As at 30 November 2025 | 510,691 | 16,365 | 210,070 | 45,882 | 783,008
Depreciation
As at 1 December 2024 | - | - | 117,404 | 34,738 | 152,142
Provided during the period | - | - | 23,166 | 4,094 | 27,260
Disposals | - | - | - | (11,804 ) | (11,804 )
As at 30 November 2025 | - | - | 140,570 | 27,028 | 167,598
Net Book Value
As at 30 November 2025 | 510,691 | 16,365 | 69,500 | 18,854 | 615,410
As at 1 December 2024 | 510,691 | 16,365 | 92,666 | 27,194 | 646,916

6. Debtors

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Due within one year
Trade debtors | 302,849 |  | 410,223
Other debtors | 3,600,766 |  | 2,925,387
| 3,903,615 |  | 3,335,610

Page 5
Page 6
Suffolk Pharma Ltd
Notes to the Financial Statements (continued)
For The Year Ended 30 November 2025
7. Creditors: Amounts Falling Due Within One Year

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Trade creditors | 308,711 |  | 499,433
Other creditors | 72,493 |  | 172,084
Taxation and social security | 163,474 |  | 184,798
| 544,678 |  | 856,315

8. Related Party Transactions
Mr Mitul Patel, Mr Sanjay Patel and Mrs Melissa Kate Peet are Directors of Suffolk Pharma Ltd.
At the balance sheet date, the total amount owed by the company to the directors is £65,749.12 (2024: £65,749.12 ).
During the year the company has declared a dividend of £0.00 (2024: £265,000.00).
9. Summary of transactions with other related parties
Hereford Hub Retail Limited
(Company associated with the directors)
Mr Mitul Patel is also the director of Hereford Hub Retail Limited.
At the balance sheet date, the amount due from Hereford Hub Retail Limited was £142,400 (2024: £142,400)
Lime Pharmacy Limited
(Company associated with the directors)
Mr Sanjay Patel, Mr Mitul Patel and Mrs Melissa Kate Peet are also the directors of Lime Pharmacy Limited.
At the balance sheet date, the amount due to Lime Pharmacy Limited was £0.00 (2024: £100,000.00)
Citrus Fruit Ltd
(Company associated with the directors)
Mr Sanjay Patel, Mr MitulPatel and Mrs Melissa Kate Peet are also the directors of Citrus Fruit Ltd .
At the balance sheet date, the amount due from Citrus Fruit Ltd was £750,000 (2024 : £850,000)
Bristol Pharma Ltd
(Company associated with the directors)
Mr Sanjay Patel and Mr Mitul Patel are also the directors of Bristol Pharma Ltd.
At the balance sheet date, the amount due from Bristol Pharma Ltd was £300,000 (2024 : £300,000)
Bhai Investment Group Ltd
(Company associated with the directors)
Mr Sanjay Patel and Mr Mitul Patel are also the directors of Bhai Investment Group Ltd .
At the balance sheet date, the amount due from Bhai Investment Group Ltd was £2,033,822.87(2024 : £1,233,822.87)
Page 6